Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -1.03M | -966.00K | -897.00K | -970.00K | EBIT |
-142.90M | -110.78M | -91.77M | -78.87M | -74.19M | EBITDA |
-142.90M | -109.75M | -91.77M | -77.97M | -74.19M | Net Income Common Stockholders |
-127.85M | -100.70M | -91.48M | -77.68M | -97.27M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
255.96M | 208.19M | 206.27M | 236.98M | 293.60M | Total Assets |
274.14M | 252.01M | 247.18M | 298.64M | 299.00M | Total Debt |
3.18M | 10.21M | 2.66M | 1.93M | 0.00 | Net Debt |
-59.41M | -13.17M | -64.18M | -224.08M | -78.45M | Total Liabilities |
31.02M | 27.92M | 24.83M | 25.67M | 9.22M | Stockholders Equity |
243.12M | 224.09M | 222.35M | 272.98M | 289.78M |
Cash Flow | Free Cash Flow | |||
-112.66M | -86.54M | -77.22M | -60.48M | -45.94M | Operating Cash Flow |
-112.66M | -85.69M | -75.14M | -59.54M | -45.27M | Investing Cash Flow |
22.14M | -43.40M | -109.25M | 158.44M | -215.96M | Financing Cash Flow |
126.55M | 85.66M | 25.62M | 49.13M | 250.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $5.14B | 59.36 | 10.34% | ― | 473.02% | 1620.44% | |
59 Neutral | $3.85B | ― | -31.41% | ― | 49.59% | 24.92% | |
53 Neutral | $897.61M | ― | -50.50% | ― | ― | 4.28% | |
49 Neutral | $6.87B | 0.03 | -54.93% | 2.50% | 24.65% | -2.90% | |
44 Neutral | $115.22M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $553.30M | ― | -54.73% | ― | ― | 7.15% | |
42 Neutral | $107.89M | ― | -54.21% | ― | -78.55% | -0.92% |
On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment to the 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 1,100,000, totaling 2,250,000 shares. This move, made without stockholder approval under Nasdaq rules, aims to attract new employees and facilitate mergers or acquisitions, aligning with the company’s strategic growth and talent acquisition objectives.
ORIC Pharmaceuticals plans to present an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting its progress in advancing two lead programs, ORIC-114 and ORIC-944, towards pivotal studies. With a strong financial position, the company is well-positioned to continue its development pipeline, targeting new investigational new drug candidates and anticipating significant data milestones in the upcoming years, which could strengthen its industry positioning and impact stakeholders by addressing unmet needs in cancer treatment.